ICM
MACK

Indaba Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Indaba Capital Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-223,459
Closed -$3M – 9
2023
Q4 		$3M Buy
223,459
+86,657
+63% +$1.1M 1.72% 7
2023
Q3 		$1.69M Buy
+136,802
New +$1.66M 0.5% 10

Other funds holding MACK

WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
SC
Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Indaba Capital Management's MACK Position: Q1 2024 in Review

Indaba Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2024, closing a stake of 223,459 shares — an estimated $3M sold.

Indaba Capital Management first reported a position in MACK in Q3 2023 and held it in 2 quarters. The position peaked at $3M in Q4 2023. 70 funds tracked by Wall St. Rank hold MACK as of Q1 2024.

  • Indaba Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • Indaba Capital Management sold 223,459 Merrimack Pharmaceuticals, Inc. shares in Q1 2024, an estimated $3M.
  • Indaba Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2023 and held it in 2 quarters.
  • Indaba Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $3M in Q4 2023.
  • 70 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2024.

Based on Indaba Capital Management's 13F filing for Q1 2024, filed 15 May 2024.